v3.26.1
Summary of Significant Accounting Policies - Schedule of Reconciliation of the Company's Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Summary of Significant Accounting Policies [Line Items]            
General and administrative expenses $ 9,769   $ 2,438   $ 17,228 $ 5,446
Research and development expenses            
Total research and development expenses 44,146   2,421   58,791 5,842
Total operating loss (53,915)   (4,859)   (76,019) (11,288)
Non-operating income (loss) 2,312   (12)   5,362 1,111
Net loss (51,603) $ (19,054) (4,871) $ (5,306) (70,657) (10,177)
Operating Segments [Member]            
Summary of Significant Accounting Policies [Line Items]            
General and administrative expenses 9,769   2,438   17,228 5,446
Research and development expenses            
Total direct research and development expenses 38,557   508   50,205 2,277
Total indirect and unallocated research and development expenses 5,589   1,913   8,586 3,565
Total research and development expenses 44,146   2,421   58,791 5,842
Total operating loss (53,915)   (4,859)   (76,019) (11,288)
Non-operating income (loss) 2,312   (12)   5,362 1,111
Net loss (51,603)   (4,871)   (70,657) (10,177)
Schizophrenia programs | Operating Segments [Member]            
Research and development expenses            
Total direct research and development expenses 31,488   (590)   37,239 487
Bipoar depression programs | Operating Segments [Member]            
Research and development expenses            
Total direct research and development expenses 2,666   0   5,672 0
Formulation and CMC | Operating Segments [Member]            
Research and development expenses            
Total direct research and development expenses 2,977   1,020   5,306 1,673
Preclinical and other direct expenses | Operating Segments [Member]            
Research and development expenses            
Total direct research and development expenses 1,426   78   1,988 117
Personnel-related | Operating Segments [Member]            
Research and development expenses            
Total indirect and unallocated research and development expenses 5,248   1,231   7,335 2,317
Consulting and other | Operating Segments [Member]            
Research and development expenses            
Total indirect and unallocated research and development expenses $ 341   $ 682   $ 1,251 $ 1,248